02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
17:55 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting KMT5A could help treat lung squamous cell carcinoma (SCC). In tumor samples from patients, BCL11A and SOX2 expression levels were higher than in...
18:35 , Aug 22, 2018 |  BC Extra  |  Preclinical News

Cambridge team identifies targets specific for squamous lung cancer

Researchers at University of Cambridge and colleagues identified an oncogene and epigenetic factors it regulates in lung squamous cell carcinoma (SCC), which could lead to new therapeutic targets for the indication. The targeted therapy landscape...
11:34 , May 16, 2018 |  BC Innovations  |  Translation in Brief

Sickle cell strides

Advances in hematopoietic stem cell mobilization procedures have enabled Bioverativ Inc. to bring its enhancer-targeted therapy, BIVV003, into the clinic for sickle cell disease. FDA accepted the IND for BIVV003 on Wednesday, and the company...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
21:27 , Oct 26, 2017 |  BC Innovations  |  Tools & Techniques

Ripe for enhancement

Although still largely the purview of academics, technologies for mapping enhancers to the genes they control are rapidly gaining efficiency and promise to unlock a trove of new targets for drug developers. But companies will...
17:59 , Feb 15, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on four genomic loci could help predict the risk of prostate cancer. Genome-wide association studies in 40,925 healthy volunteers and 5,006 prostate cancer patients identified associations between levels of the prostate cancer...
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Sickle cell disease (SCD) Mouse studies suggest an shRNA-microRNA construct targeting BCL11A in erythroid cells could help treat SCD. The construct consisted of a BCL11A -targeting shRNA sequence incorporated into a microRNA (miRNA) backbone...
07:00 , Jun 23, 2016 |  BC Innovations  |  Tools & Techniques

What GWAS will be

Karen Tkach, Staff Writer  Genome-wide association studies (GWAS) identify thousands of genetic variants that are linked to disease, without distinguishing the alleles that cause the phenotype from variants that are co-inherited but not causal. Two...
08:00 , Feb 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: B cell lymphoma 11A (BCL11A)

Cancer INDICATION: Breast cancer In vitro and mouse studies suggest inhibiting BCL11A could help treat triple negative breast cancer (TNBC). In a screen of breast cancer subtypes, high BCL11A levels caused by overexpression or copy...